Lung Fung Group Holdings Limited (Ticker: 2290 HK) is a Hong Kong-based retailer of beauty, health and pharmaceutical products, operating under the “Lung Fung” brand through 31 retail stores in Hong Kong and online sales platforms. The company is domiciled in Hong Kong and offers products across categories including proprietary Chinese medicines, western medicines, health supplements, skincare, cosmetics, fragrances, personal care, maternal and infant products, food, pet food and household daily necessities.

Lung Fung Group plans to list on the Hong Kong Stock Exchange on June 5, 2026. According to published terms, the company is offering 125.0 million primary shares at HKD 5.18-6.38 per share, raising up to approximately HKD 798 million, or about $102 million. The implied market capitalization is HKD 2.59-3.19 billion, equivalent to approximately $331-407 million.

According to the prospectus, IPO proceeds are expected to be used for R&D and product capacity, brand promotion and business development, working capital, strategic acquisitions, and other purposes. The offering includes a 15% greenshoe option and DBS Asia Capital is the sponsor.